Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Phase Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of Live Attenuated Varicella Vaccine Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (Split Virion) in Children Aged 7-12 Years

NCT06987942 is registered in ClinicalTrials.gov with Sinovac (Dalian) Vaccine Technology Co., Ltd. as lead sponsor.

NCT NCT06987942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06987942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Phase Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of Live Attenuated Varicella Vaccine Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (Split Virion) in Children Aged 7-12 Years
Lead sponsor
Sinovac (Dalian) Vaccine Technology Co., Ltd.
Phase
Phase 4
Overall status
Completed
Start date
September 21, 2024
Completion date
November 15, 2024
Enrollment
899 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza vaccine, varicella